1.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 2006-006130-17, NCT00646854
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 61 to 80 Sponsor: Other Protocol IDs: DSHNHL 2006-1B / ACT-2, BMBF GFVT 01014715, NCT00725231
|
|
4.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CM-2008-01, 08/H0720/15, 74928896, NCT01077908
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: NHLBI Protocol IDs: NHLBI-02-H-0250, NCT00047060
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
|
|
7.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TSRCC-164-2006, NCT00363090
|
|
8.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
10.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL2I, CLL2I, BAYER-GCLLSG-CLL2I, EU-20816, NCT00634881
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: CCI #07-00119, CHLA-#07-00119, NCT00730314
|
|
12.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC088C, NCI-2009-00935, 08-008775, NCT00935792
|
|
13.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-0132, NCT00943319
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AGMT CLL-6 BendAlem, NCT00951457
|
|
15.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: LS1084, NCI-2010-02329, 10-003025, NCT01269385
|
|
16.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RHM CAN0638, 2008-007043-14, NCT01422603
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 72 Sponsor: NHLBI Protocol IDs: 050206, 05-H-0206, NHLBI-05-H-0206, NCT00217594
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: MF/SS, NCT00157274
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: CDR0000462406, UCSF-04152, UCSF-00452, UCSF-H411-25738-02, NCT00301834
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 85 Sponsor: NHLBI Protocol IDs: 060190, 06-H-0190, NHLBI-06-H-0190, NCT00345345
|
|
21.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: LCC-CTRU-CLL207, SPRI-LCC-CTRU-CLL207, ISRCTN23153249, EU-20715, EUDRACT-2006-000053-22, NCT00458523, CLL207
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 55 and under Sponsor: Other Protocol IDs: 2007.00, NCI-2009-01550, P01HL036444, FHCRC-2007.00, 6301, NCT00553098
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 60 and under Sponsor: Other Protocol IDs: BCM-H-10915, H 10915, BCM-SAA-MUD, NCT00598221
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 00003567, NCT00597714
|
|
25.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000594797, MAYO-LS0881, LS0881, NCT00669318
|